Safety and Efficacy of New XXXX -eluting Stent Models in a Preclinical Study.

@entity3446 @entity32 @entity12526 @entity256
INTRODUCTION AND OBJECTIVES: Initial preclinical studies are required during the process of improving polymers, platforms, and drug-eluting systems for new coronary stent designs. Our objective was to analyze the efficacy and safety of new drug-eluting stent models compared with a conventional stent and commercialized drug-eluting stents in an experimental model with healthy porcine coronary arteries. METHODS: Sixty stents (conventional stent, new @entity3446 -eluting stents: drug-eluting stents 1, 2 and 3; Cypher(  ) and Xience(  )) were randomly placed in the coronary arteries of 20 Large White @entity12526 . Angiographic and histomorphometric studies were done 28 days later. RESULTS: The stents were implanted at a stent/artery ratio of 1.34  0.15, with no significant differences between groups. The new stents showed less late loss and angiographic @entity256 than conventional stents (P=.006 and P<.001, respectively). Histologically, @entity256 and neointimal area were lower with all the new platforms than with the conventional stents (P<.001 for each variable), and no differences were found vs the drug-eluting stents on the market. Safety data showed that endothelialization was lower with drug-eluting stents than with conventional stents, except for drug-eluting stent 3 (P=.084). Likewise, @entity32 was lower with drug-eluting stent 3 than with other stents. CONCLUSIONS: The new drug-eluting stent platforms studied are associated with less @entity256 than conventional stents and showed no significant differences in safety or efficacy vs commercialized drug-eluting stents.
